Business
Novo Nordisk and Eli Lilly both think the Wegovy pill is doing well, but the American rival sees the successful launch as a harbinger of good news for its own candidate, orforglipron, which is expected to hit the market in the second quarter.
FEATURED STORIES
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
A group of unions and consumer organizations have banded together in opposition to the $63 billion merger citing concerns that it will create a monopoly and harm competition.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.
Microbiome specialist MRM Health enters into its first industry collaboration with DuPont Nutrition & Biosciences in the field of metabolic diseases.
MRM Health also announced that it raised more than €14m to advance its clinical and preclinical development programs in the field of microbiome-based therapeutics with partner participation.
DNX Biopharmaceuticals announced that it has entered into a strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson*.
The new office reinforces Signant Health’s values and focus on customers in its layout and design
Virginia, which is part of the BioSpace Hotbed region known as BioCapital, is home to an $8 billion biopharma market that employs more than 26,545 people.
To date, there are more than 72,000 confirmed and suspected cases of COVID-19 and 1,023 deaths from COVID-19, most in mainland China.
Hector Armando Kellum, a former senior executive with the Novartis subsidiary Sandoz, pleaded guilty for his role in a price-fixing scheme for generic drugs developed by his company.
It is planned to go into operation in 2021, and is expected to create more than 200 new jobs in Lee County, North Carolina.